Day One

• Introducing the multi-faceted MUTTA platform to develop multi-epitope targeting tetravalent ADCs
• Leveraging MUTTA platform to expand development of differentiated dual targeting ADCs, screening over 50 unique target pairs to identify >15 novel dual targeting MUTTA ADCs
• Presenting preclinical data on several programs including the dual targeting MUC16 and NaPi2b ADC (AV-P138-ADC/ ARR-002)

• Navigating the complexities of ADC development from challenges in target selection and patient stratification to understanding resistance mechanisms
• Discovering how Tempus’ integrated platform uses multimodal real-world data, AI, and patient-derived organoids to help inform development strategies and support patient population identification
• Exploring how an established diagnostic engine and a connected oncologist network can help facilitate ADC adoption and support a streamlined path to commercialization

• Delving into the IND enabling profiles of bispecific ADCs NEOK001 and 002, emphasizing advantages over monospecific ADCs
• Explaining the unique characteristics of NEOK001 targeting B7-H3+ROR1 including higher need for differentiation amongst B7-H3 ADC landscape
• Breaking down early clinical development strategy and lessons learned from ongoing Phase I bispecific ADC trials

• Leveraging the RenLite common light chain to eliminate mismatching and ensure high homogeneity and "antibody-like" stability for dual payload formats
• Combining two distinct, complementary MoAs on a single molecule to tackle tumor heterogeneity and bypass resistance 
• Spotlighting RenSuper Workstation AI Platform, scanning 200+ TAA targets and 100,000s of ready-to-go antibodies to match the ideal lead with optimal internalization in record time

• Explaining development rationale for GPNMB-targeted Auristatin-S ADCs informed by the historical therapeutic index constraints observed with vedotin-based ADCs
• Outlining preclinical data showing Auristatin-S ADC preserved potency, improved tolerability and a wider therapeutic window
• Exploring opportunity to enable higher dosing and improve clinical benefit in NSCLC, esophageal cancer, head and neck cancers and melanoma

• Addressing challenges of tumor heterogeneity and poor drug penetration of solid tumors with internalization independent payload release
• Screening and identifying a unique linker using a specific TME enzyme consistently expressed across cancer models for next-generation ADC development
• Achieving superior efficacy and safety with an internalization independent linker-payload system in ductal carcinoma and squamous carcinoma cell lines 

• Outlining design and development of STRO-006, an integrin beta-6 targeted DAR8 Topo1 ADC
• Evaluating STRO-006 in a PDX clinical trial to identify biomarkers correlating with response
• Undergoing translational workstreams to enable successful clinical development 

• Evaluating how a Mouse Clinical Trial converts preclinical efficacy into a clinically shaped ORR readout, illustrated with a HER2 ADC case study
• Utilizing a payload-resistant model to reveal that resistance tracks with payload mechanism, largely independently of target antigen, reframing how backup and next-generation ADCs should be triaged
• Carrying out functional omics screens in vivo inside low-passage patient-derived tumors for novel ADC target discovery, validated on our own pipeline

• Investigating ADC case studies in early clinical development to understand how ADC preclinical profiles translate to patient impact
• Breaking down strategies from ADC case studies to best set up early clinical development for success through dosing, biomarker and trial design approaches
• Implementing lessons from ADC clinical trial successes and failures to improve ADC design and clinical outcomes

• Utilizing the site specific ConjuAll platform to build a discrete DAR ADC with circulation stable bioconjugation in combination with a proprietarty beta-glucuronidase linker 
• Exploring how ConjuAll platform design corresponds to LCB02A’s excellent preclinical therapeutic index
• Building out a clinical strategy to rapidly generate LCB02A clinical proof of concept

• Contextualizing suboptimal MUC1-N targeting properties to demonstrate benefits to MUC1-C subunit as an ADC target
• Exploring preclinical PDX safety and efficacy for XYA01/02 leading to NCI NExT program selection and IND enabling development
• Evaluating XYA01/02 trial design positioning for differentiated impact across MUC1-C-expressing epithelial carcinomas versus existing anti-MUC1 ADCs

• Maximizing therapeutic impact against low expressing targets and rapidly proliferating tumors using targeted high DAR ADC architectures
• Addressing current ADC challenges with novel linker-payloads: Preclinical proof-of-concept to preserve efficacy while enhancing ADC tolerability and therapeutic index
• Detailing novel linker mechanism for safer sequential release of MMAE

• Exploring trends and updates from preclinical and clinical ADC development • Reviewing key highlights for ADC innovation and development in 2025 and 2026
• Examining emerging ADC approaches including dual payloads, bispecific ADCs and DACs
• Visualizing the history of ADC development, giving perspective on how far the ADC space has come and where it is heading

• Accessing unique patient populations and enriching enrollment with those more likely to relapse with a comprehensive biomarker approach that integrates CGP, MRD, multi-omics, and RWD
• Detecting molecular response within weeks of therapy initiation and identifying which patients are benefiting
• Enhancing clinical development and trial designs by using ctDNA for response monitoring to allow for earlier efficacy readouts and as an early surrogate endpoint to support regulatory conversations

• Laying out the history and progress made developing ADCs and other therapeutics against c-Met
• Detailing the safety and efficacy profile of ABBV-400, focused on CRC and solid tumor indications
• Exploring future development plans and potential of ABBV 400 in impact CRC patients currently underserved by ADC therapies

This is your opportunity to present newly published first-in human and Phase I or beyond clinical data in front of our specialized audience of industry experts. Data must be published and available to be presented ahead of the deadline of Friday, September 4. Email info@hansonwade.com to register your interest.

• Leveraging HPLC with automatic probe sampling to understand process chemistries including conjugation and reduction kinetics
• Investigating applications of automatic data analysis across multiple stages of ADC process development
• Highlighting proof-of-concept for ADC process automation and ongoing use case

• Exploring the differing development approaches of ADCs across the preclinical to commercial spectrum
• Understanding how the bioconjugate landscape now encompasses a wide variety of modalities with differing MoAs and molecular structures
• Exploring relevant examples of how the requirements for process and analytical development can vary between different conjugates

• Highlighting the necessity to leverage high throughput methods and automation to accelerate ADC process and analytical characterization
• Laying out methodology is incorporate automation in PAT and increases platform throughput in ADC development
• Understanding high throughput methods for process monitoring and real time bioconjugation approaches

• Discussing an integrated platform approach that utilizes real-time PATM engineering principles, and strategic methodologies
• Outlining strategies for optimizing conjugation chemistry and dual payload conjugates 
• Exploring case studies to demonstrate how this approach enhances decision-making reduces timelines, and improves cost efficiencies in the ADC pipeline

• Exploring CMC projects to enable time, cost and sustainability-sensitive ADC manufacturing
• Contextualizing CMC strategy from a portfolio lens to manage CMC across multiple global ADC programs
• Understanding how to plan and adapt CMC approaches to accommodate for future ADC product launches without compromising manufacturing quality, cost and timelines 

• Characterizing the hazards of individual ADC components, intermediates, and the conjugated products
• Applying occupational exposure banding and evaluating the implications for ADC laboratory operations
• Reducing ADC-related risk through appropriate handling practices and exposure control strategies

• Exploring an AI-enabled, modular, antibody-agnostic linker platform to enable reproducible manufacturing of scalable dual payload ADCs
• Laying out considerations for rapid development and manufacturing of novel dual payload ADCs while maintaining cost efficiency comparable to single payload ADCs
• Demonstrating proven manufacturability and developability across multiple dual-payload ADCs

• Breaking down flexible platform strategies to translate conjugation chemistry into commercially viable process 
• Laying out case study-based CMC insights highlighting critical technical levers for successful ADC scale-up and technology transfer
• Understanding how an integrated CDMO framework can de-risk ADC scale-up by aligning early process-development decisions with cost of goods, supply-chain resilience, and regulatory CMC expectations from IND through BLA